Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 05-Sep-23 5:34 PM View:  | Boyle Kevin S. Sr. Chief Executive Officer Director | ZIOPHARM Oncology, Inc. (TCRT) | 01-Sep-23 | Sale (Planned) | 68,014 | $0.14 | $9,542.36 | (8%) 866.25K to 798.24K | |
| 01-Dec-22 4:05 PM View: | Postma Robert W Director | ZIOPHARM Oncology, Inc. (TCRT) | 29-Nov-22 | Private Purchase | 750,000 | $0.65 | $487,500.00 | 14% 5.5M to 6.25M | |
| 01-Dec-22 4:05 PM View: | Vieser Jaime Director | ZIOPHARM Oncology, Inc. (TCRT) | 29-Nov-22 | Private Purchase | 1,250,000 | $0.65 | $812,500.00 | 152% 820.32K to 2.07M | |
| 01-Sep-22 4:30 PM View: | Boyle Kevin S. Sr. Chief Executive Officer Director | ZIOPHARM Oncology, Inc. (TCRT) | 30-Aug-22 | Payment of Exercise | 18,750 | $2.41 | $45,187.50 | (2%) 885.0K to 866.25K | |
| 24-Jun-22 4:32 PM View: | Thistle Mary Director | ZIOPHARM Oncology, Inc. (TCRT) | 22-Jun-22 | Grant | 40,000 | -- | -- | 800% 5.0K to 45.0K | |
| 24-Jun-22 4:31 PM View: | Vieser Jaime Director | ZIOPHARM Oncology, Inc. (TCRT) | 22-Jun-22 | Grant | 40,000 | -- | -- | 5% 780.32K to 820.32K | |
| 24-Jun-22 4:31 PM View: | Huang James Director | ZIOPHARM Oncology, Inc. (TCRT) | 22-Jun-22 | Grant | 80,000 | -- | -- | 74% 108.33K to 188.33K | |
| 24-Jun-22 4:35 PM View: | Thistle Mary Director | ZIOPHARM Oncology, Inc. (TCRT) | 22-Jun-22 | Grant | 40,000 | -- | -- | 800% 5.0K to 45.0K | |
| 24-Jun-22 4:30 PM View: | Weis Holger Director | ZIOPHARM Oncology, Inc. (TCRT) | 22-Jun-22 | Grant | 40,000 | -- | -- | 29% 139.37K to 179.37K | |
| 24-Jun-22 4:31 PM View: | Postma Robert W Director | ZIOPHARM Oncology, Inc. (TCRT) | 22-Jun-22 | Grant | 40,000 | -- | -- | < 1% 5.46M to 5.5M | |
| 24-Jun-22 4:31 PM View: | Bowden Christopher Director | ZIOPHARM Oncology, Inc. (TCRT) | 22-Jun-22 | Grant | 40,000 | -- | -- | 960% 4.17K to 44.17K | |
| 24-Jun-22 4:35 PM View: | Huang James Director | ZIOPHARM Oncology, Inc. (TCRT) | 22-Jun-22 | Grant Duplicate | 80,000 | -- | -- | 74% 108.33K to 188.33K | |
| 24-Jun-22 4:35 PM View: | Postma Robert W Director | ZIOPHARM Oncology, Inc. (TCRT) | 22-Jun-22 | Grant | 40,000 | -- | -- | < 1% 5.46M to 5.5M | |
| 27-Dec-21 12:20 PM View: | de Groot Eleanor EVP, Operations | ZIOPHARM Oncology, Inc. (TCRT) | 22-Dec-21 | Market Sale (Planned) | 20,132 | $1.27 | $25,567.60 | (8%) 257.24K to 237.11K | < 1% |
| 17-Nov-21 4:53 PM View: | Boyle Kevin S. Sr. Chief Executive Officer Director | ZIOPHARM Oncology, Inc. (TCRT) | 17-Nov-21 | Market Purchase | 9,116 | $1.40 | $12,762.40 | 1% 875.88K to 885.0K | < 1% |
| 17-Nov-21 4:53 PM View: | Boyle Kevin S. Sr. Chief Executive Officer Director | ZIOPHARM Oncology, Inc. (TCRT) | 16-Nov-21 | Market Purchase | 884 | $1.40 | $1,237.60 | < 1% 875.0K to 875.88K | < 1% |
| 04-Oct-21 6:11 PM View: | Vieser Jaime Director | ZIOPHARM Oncology, Inc. (TCRT) | 29-Sep-21 | Market Purchase | 100,000 | $1.91 | $191,000.00 | 15% 680.32K to 780.32K | (4%) |
| 03-Sep-21 10:00 PM View: | Hagen Heidi Director | ZIOPHARM Oncology, Inc. (TCRT) | 02-Sep-21 | Market Purchase | 23,770 | $1.76 | $41,835.20 | 19% 122.12K to 145.89K | 25% |
| 03-Sep-21 5:21 PM View: | Huang James Director | ZIOPHARM Oncology, Inc. (TCRT) | 01-Sep-21 | Market Purchase | 100,000 | $1.71 | $171,000.00 | 1200% 8.33K to 108.33K | 4% |
| 31-Aug-21 4:42 PM View: | Boyle Kevin S. Sr. Chief Executive Officer Director | ZIOPHARM Oncology, Inc. (TCRT) | 30-Aug-21 | Grant | 875,000 | -- | -- | 100% 0 to 875.0K | |
| 19-May-21 4:55 PM View: | Baffa Raffaele Chief Medical Officer | ZIOPHARM Oncology, Inc. (TCRT) | 17-May-21 | Grant | 80,645 | -- | -- | 40% 200.0K to 280.64K | |
| 06-May-21 7:27 PM View: | Weis Holger Director | ZIOPHARM Oncology, Inc. (TCRT) | 04-Mar-21 | Grant | 4,167 | -- | -- | 5% 85.2K to 89.37K | |
| 06-May-21 7:24 PM View: | Postma Robert W Director | ZIOPHARM Oncology, Inc. (TCRT) | 04-Mar-21 | Grant | 2,500 | -- | -- | < 1% 5.38M to 5.38M | |
| 06-May-21 7:20 PM View: | Bowden Christopher Director | ZIOPHARM Oncology, Inc. (TCRT) | 04-Mar-21 | Grant | 4,167 | -- | -- | 100% 0 to 4.17K | |
| 06-May-21 7:21 PM View: | Buchi J Kevin Director | ZIOPHARM Oncology, Inc. (TCRT) | 04-Mar-21 | Grant | 4,167 | -- | -- | 100% 0 to 4.17K | |
| 08-Mar-21 5:28 PM View: | Hagen Heidi Interim CEO Director | ZIOPHARM Oncology, Inc. (TCRT) | 04-Mar-21 | Grant | 90,000 | -- | -- | 280% 32.12K to 122.12K | |
| 08-Mar-21 5:30 PM View: | Buck Jill EVP, GM Gene Therapy | ZIOPHARM Oncology, Inc. (TCRT) | 04-Mar-21 | Grant | 31,500 | -- | -- | 16% 199.52K to 231.02K | |
| 06-May-21 7:25 PM View: | Thistle Mary Director | ZIOPHARM Oncology, Inc. (TCRT) | 04-Mar-21 | Grant | 5,000 | -- | -- | 100% 0 to 5.0K | |
| 06-May-21 7:26 PM View: | Vieser Jaime Director | ZIOPHARM Oncology, Inc. (TCRT) | 04-Mar-21 | Grant | 4,167 | -- | -- | < 1% 676.15K to 680.32K | |
| 08-Mar-21 5:29 PM View: | Hadfield Robert Chief Legal Officer and Sec. | ZIOPHARM Oncology, Inc. (TCRT) | 04-Mar-21 | Grant | 43,500 | -- | -- | 33% 133.32K to 176.82K | |
| 08-Mar-21 5:26 PM View: | de Groot Eleanor EVP, GM Cell Therapy | ZIOPHARM Oncology, Inc. (TCRT) | 04-Mar-21 | Grant | 50,825 | -- | -- | 25% 206.41K to 257.24K | |
| 06-May-21 7:22 PM View: | Huang James Director | ZIOPHARM Oncology, Inc. (TCRT) | 04-Mar-21 | Grant | 8,333 | -- | -- | 100% 0 to 8.33K | |
| 12-Jan-21 4:35 PM View: | Buck Jill EVP, GM Gene Therapy | ZIOPHARM Oncology, Inc. (TCRT) | 08-Jan-21 | Market Sale (Planned) | 27,894 | $3.12 | $87,029.30 | (12%) 227.41K to 199.52K | (19%) |
| 12-Jan-21 4:34 PM View: | Lafond Kevin G SVP, Treasurer & CAO | ZIOPHARM Oncology, Inc. (TCRT) | 08-Jan-21 | Market Sale (Planned) | 18,020 | $3.09 | $55,681.80 | (22%) 81.98K to 63.97K | (20%) |
| 12-Jan-21 4:33 PM View: | Hadfield Robert General Counsel and Secretary | ZIOPHARM Oncology, Inc. (TCRT) | 08-Jan-21 | Market Sale (Planned) | 26,500 | $3.12 | $82,680.00 | (17%) 159.82K to 133.32K | (19%) |
| 06-Jan-21 5:03 PM View: | de Groot Eleanor EVP, GM Cell Therapy | ZIOPHARM Oncology, Inc. (TCRT) | 04-Jan-21 | Market Sale (Planned) | 21,620 | $2.72 | $58,806.40 | (9%) 228.03K to 206.41K | (37%) |
| 06-Jan-21 5:02 PM View: | Cooper Laurence James Neil President and CEO Director | ZIOPHARM Oncology, Inc. (TCRT) | 04-Jan-21 | Market Sale (Planned) | 105,693 | $2.71 | $286,428.00 | (6%) 1.9M to 1.8M | (37%) |
| 31-Jan-20 4:50 PM View: | Lafond Kevin G SVP, Treasurer & CAO | ZIOPHARM Oncology, Inc. (TCRT) | 29-Jan-20 | Grant | 18,000 | -- | -- | 28% 63.98K to 81.98K | |
| 31-Jan-20 4:51 PM View: | Mauney David M Md President | ZIOPHARM Oncology, Inc. (TCRT) | 29-Jan-20 | Grant | 80,500 | -- | -- | 41% 195.28K to 275.78K | |
| 31-Jan-20 4:48 PM View: | Hadfield Robert General Counsel and Secretary | ZIOPHARM Oncology, Inc. (TCRT) | 29-Jan-20 | Grant | 59,100 | -- | -- | 59% 100.72K to 159.82K | |
| 31-Jan-20 4:44 PM View: | Buck Jill EVP, GM Gene Therapy | ZIOPHARM Oncology, Inc. (TCRT) | 29-Jan-20 | Grant | 53,700 | -- | -- | 31% 173.71K to 227.41K | |
| 31-Jan-20 4:47 PM View: | de Groot Eleanor EVP, GM Cell Therapy | ZIOPHARM Oncology, Inc. (TCRT) | 29-Jan-20 | Grant | 53,700 | -- | -- | 31% 174.33K to 228.03K | |
| 31-Jan-20 4:52 PM View: | Shukla Sath EVP, Chief Financial Officer | ZIOPHARM Oncology, Inc. (TCRT) | 29-Jan-20 | Grant | 80,500 | -- | -- | 100% 0 to 80.5K | |
| 31-Jan-20 4:45 PM View: | Cooper Laurence James Neil Chief Executive Officer Director | ZIOPHARM Oncology, Inc. (TCRT) | 29-Jan-20 | Grant | 171,700 | -- | -- | 10% 1.73M to 1.9M | |
| 03-Jan-20 5:09 PM View: | Lafond Kevin G SVP, Treasurer & CAO | ZIOPHARM Oncology, Inc. (TCRT) | 02-Jan-20 | Market Sale (Planned) | 21,570 | $4.55 | $98,143.50 | (25%) 85.56K to 63.98K | 18% |
| 03-Jan-20 5:06 PM View: | de Groot Eleanor EVP, GM Cell Therapy | ZIOPHARM Oncology, Inc. (TCRT) | 02-Jan-20 | Market Sale (Planned) | 24,890 | $4.55 | $113,250.00 | (12%) 199.22K to 174.33K | 18% |
| 03-Jan-20 5:10 PM View: | Mauney David M Md President | ZIOPHARM Oncology, Inc. (TCRT) | 02-Jan-20 | Market Sale (Planned) | 22,394 | $4.55 | $101,893.00 | (10%) 217.67K to 195.28K | 18% |
| 03-Jan-20 5:07 PM View: | Hadfield Robert General Counsel and Secretary | ZIOPHARM Oncology, Inc. (TCRT) | 02-Jan-20 | Market Sale (Planned) | 16,853 | $4.55 | $76,681.20 | (14%) 117.57K to 100.72K | 18% |
| 03-Jan-20 5:04 PM View: | Buck Jill EVP, GM Gene Therapy | ZIOPHARM Oncology, Inc. (TCRT) | 02-Jan-20 | Market Sale (Planned) | 27,923 | $4.55 | $127,050.00 | (14%) 201.63K to 173.71K | 18% |
| 03-Jan-20 5:03 PM View: | Braunstein Scott Director | ZIOPHARM Oncology, Inc. (TCRT) | 31-Dec-19 | Grant | 31,780 | -- | -- | 100% 0 to 31.78K |
